Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Avenue Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 324.8K | 1.15M | +826.5K (+254.5%) |
| Value | $52.4K | $168.9K | +$116.5K (+222.1%) |
New holders (4)
Institutions that held Avenue Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 670,926 | $99.0K | 0.65% |
| Susquehanna International Group, LLP | 71,947 | $10.6K | 0.00% |
| Jane Street Group, LLC | 29,937 | $4.42K | 0.00% |
| JPMorgan Chase & Co | 5 | $1 | 0.00% |
Sold out (5)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Citadel Advisors LLC | 88,645 | $14.4K |
| Cubist Systematic Strategies, LLC | 10,909 | $1.76K |
| BlackRock Inc. | 1,257 | $202 |
| UBS Group AG | 1,080 | $174 |
| Barrett & Company, Inc. | 15 | $2 |